GSD:CA:TSV-Devonian Health Group Inc (CAD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.155

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

2.95K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NGEN:CA NervGen Pharma Corp

+0.02 (+0.79%)

USD 0.19B
ARCH:CA Arch Biopartners Inc

+0.01 (+0.61%)

USD 0.11B
COV:CA Covalon Technologies Ltd.

+0.04 (+1.09%)

USD 0.08B
MIR:CA MedMira Inc

-0.01 (-11.11%)

USD 0.06B
NRX:CA NurExone Biologic Inc.

+0.01 (+1.79%)

USD 0.04B
TTI:CA Thiogenesis Therapeutics Corp.

N/A

USD 0.03B
KNE:CA Kane Biotech Inc

-0.01 (-7.14%)

USD 0.02B
SBM:CA Sirona Biochem Corp

-0.01 (-14.29%)

USD 0.02B
HEM:CA Hemostemix Inc

N/A

USD 8.28M
RKV:CA Rakovina Therapeutics Inc

N/A

USD 7.22M

ETFs Containing GSD:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.90% 44% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.90% 44% F 59% D-
Trailing 12 Months  
Capital Gain 10.71% 47% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.71% 47% F 63% D
Trailing 5 Years  
Capital Gain -48.33% 45% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.33% 45% F 36% F
Average Annual (5 Year Horizon)  
Capital Gain 28.12% 83% B 74% C
Dividend Return 28.12% 83% B 74% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 99.45% 22% F 30% F
Risk Adjusted Return 28.27% 72% C 74% C
Market Capitalization 0.02B 67% D+ 70% C-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector